The C-terminal segment of the second extracellular loop of the thromboxane A 2 receptor plays an important role in platelet aggregation

Biochemical Pharmacology

Volumn 83, Issue 1, 2012, Pages 88-96

  Murad, John P ^a   Espinosa, Enma Veronica Paez ^a   Ting, Harold J ^a   Khasawneh, Fadi T ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Antagonist; Function blocking antibody; Ligand binding domain; Platelet; Thromboxane A 2 receptor

Indexed keywords

7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ANTIBODY; CARBOXY TERMINAL OF THE SECOND EXTRACELLULAR LOOP ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBOXANE A2 RECEPTOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTICOAGULATION; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BINDING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALS; BINDING SITES; HUMANS; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; PLATELET AGGREGATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2;

EID: 81855176161     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.10.002     Document Type: Article

References (53)

1. M. Okuma, T. Hirata, F. Ushikubi, A. Kakizuka, and S. Narumiya Molecular characterization of a dominantly inherited bleeding disorder with impaired platelet responses to thromboxane A2 Pol J Pharmacol 48 1996 77 82
2. M.L. Ogletree Overview of physiological and pathophysiological effects of thromboxane A2 Fed Proc 46 1987 133 138
3. G.A. FitzGerald, C. Healy, and J. Daugherty Thromboxane A2 biosynthesis in human disease Fed Proc 46 1987 154 158
4. J.A. Oates, G.A. FitzGerald, R.A. Branch, E.K. Jackson, H.R. Knapp, and L.J. Roberts 2nd Clinical implications of prostaglandin and thromboxane A2 formation (1) N Engl J Med 319 1988 689 698
5. C. Patrono, G. Ciabattoni, and G. Davi Thromboxane biosynthesis in cardiovascular diseases Stroke 21 1990 IV130 IV133
6. Collaborative overview of randomised trials of antiplatelet therapy-I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration Br Med J 308 1994 81 106
7. B.S. Coller Platelets and thrombolytic therapy N Engl J Med 322 1990 33 42
8. W.S. Fields, N.A. Lemak, R.F. Frankowski, and R.J. Hardy Controlled trial of aspirin in cerebral ischemia Stroke 8 1977 301 314
9. E. Genton, M. Gent, J. Hirsh, and L.A. Harker Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (first of three parts) N Engl J Med 293 1975 1174 1178
10. C. Patrono Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back Trends Pharmacol Sci 10 1989 453 458
11. M. Verstraete Are agents affecting platelet functions clinically useful? Am J Med 61 1976 897 914
12. H.J. Weiss Antiplatelet drugs-a new pharmacologic approach to the prevention of thrombosis Am Heart J 92 1976 86 102
13. R.J. Clarke, G. Mayo, P. Price, and G.A. FitzGerald Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin N Engl J Med 325 1991 1137 1141
14. C. Patrono Aspirin as an antiplatelet drug N Engl J Med 330 1994 1287 1294
15. S.J. Brister, and M.R. Buchanan Aspirin "resistance" and its impact on cardiovascular morbidity and mortality: it is real, clinically relevant and should be measured Heart 95 2009 1223 1224
16. A.I. Schafer Antiplatelet therapy Am J Med 101 1996 199 209
17. L.V. Parise, D.L. Venton, and G.C. Le Breton Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction J Pharmacol Exp Ther 228 1984 240 244
18. L.V. Parise, D.L. Venton, and G.C. Le Breton Thromboxane A2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP J Pharmacol Exp Ther 222 1982 276 281
19. W.K. Pollock, R.A. Armstrong, L.J. Brydon, R.L. Jones, and D.E. MacIntyre Thromboxane-induced phosphatidate formation in human platelets. Relationship to receptor occupancy and to changes in cytosolic free calcium Biochem J 219 1984 833 842
20. L.D. Brace, D.L. Venton, and G.C. Le Breton Thromboxane A2/prostaglandin H2 mobilizes calcium in human blood platelets Am J Physiol 249 1985 H1 H7
21. L.D. Brace, D.L. Venton, and G.C. Le Breton Reversal of thromboxane A2/prostaglandin H2 and ADP-induced calcium release in intact platelets Am J Physiol 249 1985 H8 H13
22. J.M. Bailey Prostaglandins, leukotrienes, and lipoxins: biochemistry, mechanism of action, and clinical applications 1985 Plenum Press New York
23. A.J. Cayatte, Y. Du, J. Oliver-Krasinski, G. Lavielle, T.J. Verbeuren, and R.A. Cohen The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis Arterioscler Thromb Vasc Biol 20 2000 1724 1728
24. N.I. Ghali, E.J. Kattelman, S.C. Hung, K.E. Schnorf, G.C. Le Breton, and D.L. Venton Synthesis of [17,18-3H] trans-13-azaprostanoic acid. A labeled probe for the PGH2/TXA2 receptor Prostaglandins 27 1984 865 876
25. S.C. Hung, N.I. Ghali, D.L. Venton, and G.C. Le Breton Specific binding of the thromboxane A2 antagonist 13-azaprostanoic acid to human platelet membranes Biochim Biophys Acta 728 1983 171 178
26. D.L. Venton, S.E. Enke, and G.C. Le Breton Azaprostanoic acid derivatives. Inhibitors of arachidonic acid induced platelet aggregation J Med Chem 22 1979 824 830
27. G.C. Le Breton, D.L. Venton, S.E. Enke, and P.V. Halushka 13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor Proc Natl Acad Sci U S A 76 1979 4097 4101
28. 2+ release from isolated platelet membrane vesicles Biochim Biophys Acta 751 1983 66 73
29. M.L. Ogletree, D.N. Harris, R. Greenberg, M.F. Haslanger, and M. Nakane Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist J Pharmacol Exp Ther 234 1985 435 441
30. 125I Tetrahedron Lett 25 1984 4207 4210
31. H. Patscheke, K. Stegmeier, B. Muller-Beckmann, G. Sponer, C. Staiger, and G. Neugebauer Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death Biomed Biochim Acta 43 1984 S312 S318
32. F.T. Khasawneh, J.S. Huang, J.W. Turek, and G.C. Le Breton Differential mapping of the amino acids mediating agonist and antagonist coordination with the human thromboxane A2 receptor protein J Biol Chem 281 2006 26951 26965
33. F.T. Khasawneh, J.S. Huang, F. Mir, S. Srinivasan, C. Tiruppathi, and G.C. Le Breton Characterization of isoprostane signaling: evidence for a unique coordination profile of 8-iso-PGF(2alpha) with the thromboxane A(2) receptor, and activation of a separate cAMP-dependent inhibitory pathway in human platelets Biochem Pharmacol 75 2008 2301 2315
34. K.H. Ruan, S.P. So, J. Wu, D. Li, A. Huang, and J. Kung Solution structure of the second extracellular loop of human thromboxane A2 receptor Biochemistry 40 2001 275 280
35. S.P. So, J. Wu, G. Huang, A. Huang, D. Li, and K.H. Ruan Identification of residues important for ligand binding of thromboxane A2 receptor in the second extracellular loop using the NMR experiment-guided mutagenesis approach J Biol Chem 278 2003 10922 10927
36. C.H. Ruan, J. Wu, and K.H. Ruan A strategy using NMR peptide structures of thromboxane A2 receptor as templates to construct ligand-recognition pocket of prostacyclin receptor BMC Biochem 6 2005 23
37. C. Borg, S.C. Lam, J.P. Dieter, C.T. Lim, D. Komiotis, and D.L. Venton Anti-peptide antibodies against the human blood platelet thromboxane A2/prostaglandin H2 receptor. Production, purification and characterization Biochem Pharmacol 45 1993 2071 2078
38. J.W. Turek, T. Halmos, N.L. Sullivan, K. Antonakis, and G.C. Le Breton Mapping of a ligand-binding site for the human thromboxane A2 receptor protein J Biol Chem 277 2002 16791 16797
39. E.J. Kattelman, D.L. Venton, and G.C. Le Breton Characterization of U46619 binding in unactivated, intact human platelets and determination of binding site affinities of four TXA2/PGH2 receptor antagonists (13-APA, BM 13. 177, ONO 3708 and SQ 29,548) Thromb Res 41 1986 471 481
40. M.M. Marczewski, M. Postula, and D. Kosior Novel antiplatelet agents in the prevention of cardiovascular complications-focus on ticagrelor Vasc Health Risk Manage 6 2010 419 429
41. J.D. Wichard, A. Ter Laak, G. Krause, N. Heinrich, R. Kuhne, and G. Kleinau Chemogenomic analysis of G-protein coupled receptors and their ligands deciphers locks and keys governing diverse aspects of signalling PLoS One 6 2011 e16811
42. H. Takayama, Y. Hosaka, K. Nakayama, K. Shirakawa, K. Naitoh, and T. Matsusue A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex J Clin Invest 118 2008 1785 1795
43. S. Radestock, T. Weil, and S. Renner Homology model-based virtual screening for GPCR ligands using docking and target-biased scoring J Chem Inf Model 48 2008 1104 1117
44. S. Costanzi On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor J Med Chem 51 2008 2907 2914
45. I. Canobbio, L. Stefanini, G.F. Guidetti, C. Balduini, and M. Torti A new role for FcgammaRIIA in the potentiation of human platelet activation induced by weak stimulation Cell Signal 18 2006 861 870
46. E.L. Mazzaferri Jr., and J.J. Young Abciximab: a review and update for clinicians Expert Rev Cardiovasc Ther 6 2008 609 618
47. S. Lajus, G. Clofent-Sanchez, C. Jais, P. Coste, P. Nurden, and A. Nurden Thrombocytopenia after abciximab use results from different mechanisms Thromb Haemost 103 2010 651 661
48. T.D. Watson, J.E. Stark, and K.S. Vesta Pantoprazole-induced thrombocytopenia Ann Pharmacother 40 2006 758 761
49. Z. Zhu, and L. Yan Next generation of antibody therapy for cancer Chin J Cancer 30 2011 293 302
50. J. Niles Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis Clin Exp Immunol 164 Suppl. 1 2011 27 30
51. Norman P. Monoclonal antibodies in the pipeline: a segment of major growth. Insight Pharma Reports; 2011. p. 173.
52. R.E. Scharf, M.M. Rahman, and H. Seidel The impact and management of acquired platelet dysfunction Hamostaseologie 31 2011 28 40
53. H. Ishihara, D. Zeng, A.J. Connolly, C. Tam, and S.R. Coughlin Antibodies to protease-activated receptor 3 inhibit activation of mouse platelets by thrombin Blood 91 1998 4152 4157